Oral Opportunity in PsO (US) 2024, highlights a shifting landscape in the treatment for moderate-to-severe PsO. As emerging oral therapies gain traction, the study underscores their potential to ...

Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...

InnoCare Pharma has announced that its Phase II clinical study of the Tyrosine Kinase 2 (TYK2) inhibitor ICP-488 for ...

The actress and entertainment personality partnered with Amgen to share candid glimpses of how she lives with her medical ...

In most cases, an outbreak of guttate psoriasis lasts two to three weeks. But your doctor may want to treat your symptoms and help prevent other infections in your body. Is guttate psoriasis ...

According to a 2021 review, nail psoriasis can be challenging to treat, but treatment is possible. The best approach for you may depend on your specific symptoms and their severity. Keep reading ...

InnoCare Pharma’s tyrosine kinase 2 (TYK2) inhibitor has hit the main goals of a phase 2 trial in China, sustaining the ...

Plaque psoriasis is a chronic condition that affects millions yet is often misunderstood or underappreciated in terms of its ...

Alex Thompson CFA, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Oruka Therapeutics (ORKA). Alex Thompson CFA has given ...

Researchers have potentially discovered the cause of a chronic condition called psoriasis, a disorder that causes scaly, red ...

Home-based phototherapy for plaque and guttate psoriasis is as effective as office-based phototherapy, results of the ...

Study findings reveals a 1-way relationship between cardiovascular disease and psoriasis, with no impact on other ...